Sodium Butyrate Promotes Apoptosis in Breast Cancer Cells Through Reactive Oxygen Species (ROS) Formation and Mitochondrial Impairment

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2017 Nov 4

PMID 29096636

Citations 68

Authors

Vahid Salimi

Zahra Shahsavari

Banafsheh Safizadeh

Ameinh Hosseini

Narges Khademian

Masoumeh Tavakoli-Yaraki

Affiliations

Soon will be listed here.

Abstract

Background: Sodium butyrate (NaBu) is a short-chain fatty acid which serves as a histon deacetylase inhibitor and has received considerable interest as a possible regulator of cancer cell death. The regulatory effect of NaBu on cancer cell growth or death has yet to be illustrated in many cancers including breast cancer. This study is aimed to elucidate the possible effect of NaBu on regulation of breast cancer growth and apoptosis.

Methods: The cytotoxic effect of NaBu on the growth of breast cancer cells (MCF-7 and MDA-MB-468) and normal breast cells (MCF-10A) was determined using MTT assay. Annexin-V-FITC staining and PI staining were performed to detect apoptosis and cell cycle distribution using Flow cytometry, the level of mitochondrial membrane potential (Δψm), Reactive oxygen species (ROS)formation and caspase activity were determined accordingly.

Results: Based on our data, NaBu induced a dose and time-dependent cell toxicity in breast cancer cells which was related to the cell cycle arrest and induction of apoptosis. The impact of NaBu on MCF-10A cell toxicity, cell cycle distribution and apoptosis was inconsiderable. NaBu-elicited apoptosis was accompanied by the elevated level of ROS, increased caspase activity and reduced mitochondrial membrane potential (Δψm) in MCF-7 and MDA-MB-468 cells and with no effect on the above mentioned factors in MCF-10A cells.

Conclusions: Our study provided insight in to the role of NaBu on the regulation of breast cancer cell growth and lighten up the pro-apoptotic activity of NaBu.

Citing Articles

SWATH-MS insights on sodium butyrate effect on mAbs production and redox homeostasis in CHO cells.

Galli M, Liu L, Sim K, Kok Y, Wongtrakul-Kish K, Nguyen-Khuong T AMB Express. 2024; 14(1):140.

PMID: 39718710 PMC: 11668706. DOI: 10.1186/s13568-024-01807-z.

The oral-gut microbiome axis in breast cancer: from basic research to therapeutic applications.

Huang L, Jiang C, Yan M, Wan W, Li S, Xiang Z Front Cell Infect Microbiol. 2024; 14():1413266.

PMID: 39639864 PMC: 11617537. DOI: 10.3389/fcimb.2024.1413266.

Integrating immunotherapy with conventional treatment regime for breast cancer patients- an amalgamation of armamentarium.

Nandi D, Sharma D Front Immunol. 2024; 15:1477980.

PMID: 39555066 PMC: 11563812. DOI: 10.3389/fimmu.2024.1477980.

Integrated analysis of microbiota and gut microbial metabolites in blood for breast cancer.

Peng Y, Gu J, Liu F, Wang P, Wang X, Si C mSystems. 2024; 9(11):e0064324.

PMID: 39422470 PMC: 11575300. DOI: 10.1128/msystems.00643-24.

The role of short-chain fatty acids in cancer prevention and cancer treatment.

Kalyanaraman B, Cheng G, Hardy M Arch Biochem Biophys. 2024; 761:110172.

PMID: 39369836 PMC: 11784870. DOI: 10.1016/j.abb.2024.110172.

References

Kim H, Bae S . Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011; 3(2):166-79. PMC: 3056563. View

Natoni F, Diolordi L, Santoni C, Gilardini Montani M . Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim Biophys Acta. 2005; 1745(3):318-29. DOI: 10.1016/j.bbamcr.2005.07.003. View

Tavakoli-Yaraki M, Karami-Tehrani F, Salimi V, Sirati-Sabet M . Induction of apoptosis by Trichostatin A in human breast cancer cell lines: involvement of 15-Lox-1. Tumour Biol. 2012; 34(1):241-9. DOI: 10.1007/s13277-012-0544-7. View

Mandal M, Kumar R . Bcl-2 expression regulates sodium butyrate-induced apoptosis in human MCF-7 breast cancer cells. Cell Growth Differ. 1996; 7(3):311-8. View

Kasibhatla S, Tseng B . Why target apoptosis in cancer treatment?. Mol Cancer Ther. 2003; 2(6):573-80. View

Rodrigues M, Carvalho E, Pezzuto P, Rumjanek F, Dias Amoedo N . Reciprocal modulation of histone deacetylase inhibitors sodium butyrate and trichostatin A on the energy metabolism of breast cancer cells. J Cell Biochem. 2014; 116(5):797-808. DOI: 10.1002/jcb.25036. View

McIlwain D, Berger T, Mak T . Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 2015; 7(4). PMC: 4382736. DOI: 10.1101/cshperspect.a026716. View

Abe M, Kufe D . Effect of sodium butyrate on human breast carcinoma (MCF-7) cellular proliferation, morphology, and CEA production. Breast Cancer Res Treat. 1984; 4(4):269-74. DOI: 10.1007/BF01806038. View

Bhat A, Dar K, Anees S, Zargar M, Masood A, Sofi M . Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight. Biomed Pharmacother. 2015; 74:101-10. DOI: 10.1016/j.biopha.2015.07.025. View

10.

Salimi V, Shabani M, Nourbakhsh M, Tavakoli-Yaraki M . Involvement of 15-lipoxygenase-1 in the regulation of breast cancer cell death induced by sodium butyrate. Cytotechnology. 2016; 68(6):2519-2528. PMC: 5101322. DOI: 10.1007/s10616-016-9972-3. View

11.

Zhou Q, Dalgard C, Wynder C, Doughty M . Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells. BMC Neurosci. 2011; 12:50. PMC: 3123242. DOI: 10.1186/1471-2202-12-50. View

12.

Sun B, Liu R, Xiao Z, Zhu X . c-MET protects breast cancer cells from apoptosis induced by sodium butyrate. PLoS One. 2012; 7(1):e30143. PMC: 3257283. DOI: 10.1371/journal.pone.0030143. View

13.

Louis M, Rosato R, Brault L, Osbild S, Battaglia E, Yang X . The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress. Int J Oncol. 2004; 25(6):1701-11. View

14.

Li Z, Wang Y, Yuan C, Zhu Y, Qiu J, Zhang W . Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer. Lab Invest. 2014; 94(12):1431-45. DOI: 10.1038/labinvest.2014.123. View

15.

Mirzaei A, Tavoosidana G, Rad A, Rezaei F, Tavakoli-Yaraki M, Kadijani A . A new insight into cancer stem cell markers: Could local and circulating cancer stem cell markers correlate in colorectal cancer?. Tumour Biol. 2015; 37(2):2405-14. DOI: 10.1007/s13277-015-3989-7. View

16.

Glozak M, Sengupta N, Zhang X, Seto E . Acetylation and deacetylation of non-histone proteins. Gene. 2005; 363:15-23. DOI: 10.1016/j.gene.2005.09.010. View

17.

Semini G, Hildmann A, Von Haefen C, Danker K . Glycosidated phospholipids - a promising group of anti-tumour lipids. Anticancer Agents Med Chem. 2014; 14(4):607-17. DOI: 10.2174/1871520614666140309222845. View

18.

Zhang C, Yu H, Shen Y, Ni X, Shen S, Das U . Polyunsaturated fatty acids trigger apoptosis of colon cancer cells through a mitochondrial pathway. Arch Med Sci. 2015; 11(5):1081-94. PMC: 4624753. DOI: 10.5114/aoms.2015.54865. View

19.

Wilson A, Byun D, Popova N, Murray L, LItalien K, Sowa Y . Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006; 281(19):13548-13558. DOI: 10.1074/jbc.M510023200. View

20.

Cao Q, Qian S, Wang N, Zhang L, Wang W, Shen H . TRPM2 mediates histone deacetylase inhibition-induced apoptosis in bladder cancer cells. Cancer Biother Radiopharm. 2015; 30(2):87-93. DOI: 10.1089/cbr.2014.1697. View